Showing results (261-270 of 302) with videos related to
Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancerOle Johan Halvorsen, Kari Rostad, Anne Margrete Øyan, et al.Oncotarget|July 8, 2016
Androgen receptor as potential therapeutic target in metastatic endometrial cancerIngvild Løberg Tangen, Therese Bredholt Onyango, Reidun Kopperud, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 20, 2012
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomasHenrica M J Werner, Anna Berg, Elisabeth Wik, et al.International Journal of Oncology|December 5, 2006
ERG upregulation and related ETS transcription factors in prostate cancerKari Rostad, Monica Mannelqvist, Ole Johan Halvorsen, et al.Gene Therapy|March 14, 2024
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, et al.Scientific Data|January 3, 2018
Transcriptomic analysis of gene signatures associated with sickle painJinny A Paul, Anupam Aich, Juan E Abrahante, et al.Frontiers in Medicine|September 13, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveMaria E Sheean, Frauke Naumann-Winter, Giuseppe Capovilla, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2024
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in EuropeGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2023
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.Plos One|May 23, 2014
Switch in FOXA1 status associates with endometrial cancer progressionIngvild Løberg Tangen, Camilla Krakstad, Mari K Halle, et al.Pageof 31